Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados Biol. Res. (2) Autor ARANDA,EVELYN (2) OWEN,GARETH I (2) KATO,SUMIE (1) MEDINA,RODOLFO A (1) VERDUGO,CESAR (1) Palavra-chave Angiogenesis (1) Atherosclerosis cardiovascular disease (1) EA.hy926 (1) Endothelial (1) Estrogen (1) Formula (1) HUVEC (1) Hormone replacement therapy (HRT) (1) In vitro assay (1) Matrigel (1) Myocardial infarction (1) Oral contraceptives (1) Progestins (1) Venous thrombosis (1) Mais... Tipo do documento Journal article (2) Ano 2009 (1) 2003 (1) País Chile (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última A semi-quantitative assay to screen for angiogenic compounds and compounds with angiogenic potential using the EA.hy926 endothelial cell line Biol. Res. ARANDA,EVELYN; OWEN,GARETH I. Angiogenesis, the development of new capillary vessels, has a host of clinical manifestations. The identification of agents that increase or decrease angiogenesis is of great pharmaceutical interest. Classically, in vitro angiogenesis utilizes human umbilical vein endothelial cells (HUVEC) grown in matrigel. This valid and simple method has the drawbacks that each cell population is distinct and the constraint of obtaining primary source material. Herein we utilize the established EA.hy926 endothelial cell line as our model for in vitro angiogenesis and present a novel formula to quantify endothelial cell remodeling to identify pro- and anti-angiogenic agents. Furthermore, our technique details the procedures to identify and quantify compounds that have... Tipo: Journal article Palavras-chave: Angiogenesis; EA.hy926; HUVEC; Endothelial; Formula; In vitro assay; Matrigel. Ano: 2009 URL: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602009000300012 The action of ovarian hormones in cardiovascular disease Biol. Res. MEDINA,RODOLFO A; ARANDA,EVELYN; VERDUGO,CESAR; KATO,SUMIE; OWEN,GARETH I. The incidence of cardiovascular disease (CAD) differs between men and women, in part because of differences in risk factors and hormones. This sexual dimorphism means a lower incidence in atherosclerotic diseases in premenopausal women, which subsequently rises in postmenopausal women to eventually equal that of men. These observations point towards estrogen and progesterone playing a lifetime protective role against CAD in women. As exogenous estrogen and estrogen plus progesterone preparations produce significant reductions in low-density lipoprotein (LDL) cholesterol levels and significant increases in high-density lipoprotein (HDL) cholesterol, this should in theory lower the risk of CAD. However, results from oral contraceptive (OC) use and combined... Tipo: Journal article Palavras-chave: Hormone replacement therapy (HRT); Oral contraceptives; Atherosclerosis cardiovascular disease; Estrogen; Progestins; Venous thrombosis; Myocardial infarction. Ano: 2003 URL: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602003000300005 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco